These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 24761422)

  • 21. Cell-free DNA levels in plasma of patients with non-small-cell lung cancer and inflammatory lung disease.
    Szpechcinski A; Chorostowska-Wynimko J; Struniawski R; Kupis W; Rudzinski P; Langfort R; Puscinska E; Bielen P; Sliwinski P; Orlowski T
    Br J Cancer; 2015 Jul; 113(3):476-83. PubMed ID: 26125447
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Circulating free plasma tumor DNA in patients with advanced gastric cancer receiving systemic chemotherapy.
    Normando SRC; Delgado PO; Rodrigues AKSB; David Filho WJ; Fonseca FLA; Cruz FJSM; Del Giglio A
    BMC Clin Pathol; 2018; 18():12. PubMed ID: 30498396
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Influence of Different Therapies on EGFR Mutants by Circulating Cell-free DNA of Lung Adenocarcinoma and Prognosis].
    Su F; Zheng K; Fu Y; Wu Q; Tang Y; Wang W; Jiang L
    Zhongguo Fei Ai Za Zhi; 2018 May; 21(5):389-396. PubMed ID: 29764589
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
    Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
    Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LINE-1 hypomethylation status of circulating cell-free DNA in plasma as a biomarker for colorectal cancer.
    Nagai Y; Sunami E; Yamamoto Y; Hata K; Okada S; Murono K; Yasuda K; Otani K; Nishikawa T; Tanaka T; Kiyomatsu T; Kawai K; Nozawa H; Ishihara S; Hoon DS; Watanabe T
    Oncotarget; 2017 Feb; 8(7):11906-11916. PubMed ID: 28060757
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Quantification of Circulating Free DNA as a Diagnostic Marker in Gall Bladder Cancer.
    Kumari S; Tewari S; Husain N; Agarwal A; Pandey A; Singhal A; Lohani M
    Pathol Oncol Res; 2017 Jan; 23(1):91-97. PubMed ID: 27475647
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Age-stratified reference intervals unlock the clinical potential of circulating cell-free DNA as a biomarker of poor outcome for healthy individuals and patients with colorectal cancer.
    Ørntoft MW; Jensen SØ; Øgaard N; Henriksen TV; Ferm L; Christensen IJ; Reinert T; Larsen OH; Nielsen HJ; Andersen CL
    Int J Cancer; 2021 Apr; 148(7):1665-1675. PubMed ID: 33320961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High levels of cell-free DNA accurately predict late acute kidney injury in patients after cardiac surgery.
    Merkle J; Daka A; Deppe AC; Wahlers T; Paunel-Görgülü A
    PLoS One; 2019; 14(6):e0218548. PubMed ID: 31211810
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Circulating cell-free DNA as predictor of treatment failure after neoadjuvant chemo-radiotherapy before surgery in patients with locally advanced rectal cancer.
    Schou JV; Larsen FO; Sørensen BS; Abrantes R; Boysen AK; Johansen JS; Jensen BV; Nielsen DL; Spindler KL
    Ann Oncol; 2018 Mar; 29(3):610-615. PubMed ID: 29253083
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prediction of the efficacy of immunotherapy by measuring the integrity of cell-free DNA in plasma in colorectal cancer.
    Kitahara M; Hazama S; Tsunedomi R; Takenouchi H; Kanekiyo S; Inoue Y; Nakajima M; Tomochika S; Tokuhisa Y; Iida M; Sakamoto K; Suzuki N; Takeda S; Ueno T; Yamamoto S; Yoshino S; Nagano H
    Cancer Sci; 2016 Dec; 107(12):1825-1829. PubMed ID: 27663862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating Cell-Free DNA and Circulating Tumor Cells as Prognostic and Predictive Biomarkers in Advanced Non-Small Cell Lung Cancer Patients Treated with First-Line Chemotherapy.
    Coco S; Alama A; Vanni I; Fontana V; Genova C; Dal Bello MG; Truini A; Rijavec E; Biello F; Sini C; Burrafato G; Maggioni C; Barletta G; Grossi F
    Int J Mol Sci; 2017 May; 18(5):. PubMed ID: 28492516
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The analysis of cell-free DNA concentrations and integrity in serum of initial and treated of lymphoma patients.
    Wu J; Tang W; Huang L; Hou N; Wu J; Cheng X; Ma D; Qian P; Shen Q; Guo W; Peng W; Liu Y; Jiang C; Feng J
    Clin Biochem; 2019 Jan; 63():59-65. PubMed ID: 30292543
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Application of Circulating Tumor Cells and Circulating Free DNA from Peripheral Blood in the Prognosis of Advanced Gastric Cancer.
    Yu P; Zhu S; Luo Y; Li G; Pu Y; Cai B; Zhang C
    J Oncol; 2022; 2022():9635218. PubMed ID: 35058982
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The diagnostic value of circulating cell free DNA quantification in non-small cell lung cancer: A systematic review with meta-analysis.
    Jiang T; Zhai C; Su C; Ren S; Zhou C
    Lung Cancer; 2016 Oct; 100():63-70. PubMed ID: 27597282
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Increased level and fragmentation of plasma circulating cell-free DNA are diagnostic and prognostic markers for renal cell carcinoma.
    Yamamoto Y; Uemura M; Nakano K; Hayashi Y; Wang C; Ishizuya Y; Kinouchi T; Hayashi T; Matsuzaki K; Jingushi K; Kato T; Kawashima A; Ujike T; Nagahara A; Fujita K; Imamura R; Nonomura N
    Oncotarget; 2018 Apr; 9(29):20467-20475. PubMed ID: 29755665
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Elevated plasma cfDNA may be associated with active lupus nephritis and partially attributed to abnormal regulation of neutrophil extracellular traps (NETs) in patients with systemic lupus erythematosus.
    Zhang S; Lu X; Shu X; Tian X; Yang H; Yang W; Zhang Y; Wang G
    Intern Med; 2014; 53(24):2763-71. PubMed ID: 25500436
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Analysis of Cell-Free DNA to Assess Risk of Tumoremia Following Endoscopic Ultrasound Fine-Needle Aspiration of Pancreatic Adenocarcinomas.
    Levy MJ; Kipp BR; Milosevic D; Schneider AR; Voss JS; Avula R; Kerr SE; Henry MR; Highsmith E; Liu MC; Gleeson FC
    Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1632-1640.e1. PubMed ID: 29526691
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High mutation burden of circulating cell-free DNA in early-stage breast cancer patients is associated with a poor relapse-free survival.
    Kujala J; Hartikainen JM; Tengström M; Sironen R; Kosma VM; Mannermaa A
    Cancer Med; 2020 Aug; 9(16):5922-5931. PubMed ID: 32602248
    [TBL] [Abstract][Full Text] [Related]  

  • 39. High levels of circulating cell-free DNA are a biomarker of active SLE.
    Xu Y; Song Y; Chang J; Zhou X; Qi Q; Tian X; Li M; Zeng X; Xu M; Zhang W; Cram DS; Liu J
    Eur J Clin Invest; 2018 Nov; 48(11):e13015. PubMed ID: 30079480
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A prospective study of total plasma cell-free DNA as a predictive biomarker for response to systemic therapy in patients with advanced non-small-cell lung cancers.
    Li BT; Drilon A; Johnson ML; Hsu M; Sima CS; McGinn C; Sugita H; Kris MG; Azzoli CG
    Ann Oncol; 2016 Jan; 27(1):154-9. PubMed ID: 26487589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.